Key barriers to women’s access to HIV treatment: Making ‘Fast-Track’ a reality

Background
An overdue effort

In collaboration with UN Women, ATHENA Network, AVAC, and Salamander Trust have undertaken a global multi-stage review of the status of access to antiretroviral therapy (ART) for women living with HIV.¹ Since the beginning of the HIV epidemic, this is the first ever peer-led global study of care and treatment access for women living with HIV of this scale. It is well overdue.

The global review comes at a critical juncture in the epidemic where there is an increased focus being placed on strategic investments in health guided by specific national and regional epidemiological contexts. New data from the START trial², in which roughly one-third of participants were women, offers evidence for the potential individual benefit of starting treatment sooner – that is if a person is ready and able to remain on treatment. There is also an increased push for the use of ART by people living with HIV as the primary means of achieving epidemic control. This emphasis on ART as central to “ending AIDS”, is happening in the context of a constrained resource envelope for HIV and health overall.

To achieve current global goals, it is critical to understand and address key barriers to and facilitators of women’s access to HIV treatment.

¹. Tenofovir-based pre-exposure prophylaxis (PrEP) using daily dosing of one or two antiretrovirals (ARVs) is being introduced as HIV prevention for HIV-negative men and women. This use is not considered in this review.
In this context, it is essential to understand the barriers to and facilitators of women’s access to ART, so that individual choices about when and whether to start, and continue with, treatment translate into positive mental and physical health outcomes for the woman, as well as benefiting public health.

In this review, socio-structural factors were explored at macro-, meso- and micro-levels in order to better understand the experiences women living with HIV have of treatment availability and their decision-making around uptake, and to assess how treatment programmes are affecting their lives. Removing barriers and changing policies and programmes to align with best practices will contribute substantially to efforts for the achievement of global goals such as the ‘90-90-90’ UNAIDS ‘Fast-Track’ targets.

Conventional measurements of national HIV care and treatment programmes include coverage and access. Coverage measures are used to quantify the reach of ART at population level, with measures of long-term viral suppression and retention providing proxy indicators of programmatic effectiveness. But there are levels of effectiveness and programme components that are not included in these measures, compounded by gaps in the development of sex/gender-disaggregated coverage data. Improving definitions and filling gaps are both critical to understanding effectiveness in reaching women with services that are delivered in a human rights framework and provide benefit on an individual and population level.5

Access to ART is defined in terms of availability, affordability, acceptability and quality, with measurement methods including; cost, income, geographic location, cultural and social acceptability, availability of technology, expected health gain, performance of provider and adherence. Current accessibility measures are limited by their focus on health system service delivery and are unable to address the critical points of intersection within the gendered experiences of women. Social, cultural, economic and environmental factors all influence access to treatment for women (i.e. access to economic resources, decision-making power, division of labour in the household, discrimination and stigma, etc.).

This review aims to broaden the conventional understanding of indicators of access to understand women’s perspectives and the underlying causes of barriers to access, particularly at household and community levels. With the final analysis due later in 2015, the review will propose possible new dimensions and measures of access for consideration, as well as identifying strategies currently being tested to address structural factors.

3. HIV-related structural factors are defined as barriers to, or facilitators of, an individual’s HIV treatment behaviours; they may relate to economic, social, policy, organizational or other aspects of the environment. Sumartojo E., AIDS. 2000 Jun;14 Suppl 1:S3-10.
4. The UNAIDS Fast Track goals include the following targets: By 2020: 90% of all people living with HIV will know their HIV status; 90% of all people with diagnosed HIV infection will receive sustained antiretroviral therapy; 90% of all people receiving antiretroviral therapy will have viral suppression.

The review
A unique methodology: women led and governed

The global review took as its starting point the major gaps regarding information on women’s access to HIV care and treatment across the lifecycle, and in particular for adolescent girls and women not currently pregnant.

The three phases of the review included: 1) A literature review related to women’s access to treatment and an unprecedented analysis of all available sex-disaggregated data from PEPFAR (United States President’s Emergency Plan for AIDS Relief), Global Fund for AIDS, Tuberculosis and Malaria, UNAIDS and other sources; 2) Community dialogues via focus group discussions (FGDs) in Bolivia, Cameroon, Nepal and Tunisia of 175 women, one-to-one interviews (13) and an online discussion group (15); 3) Country case studies undertaken in Kenya, Uganda and Zimbabwe with in-depth focus groups, one-to-one interviews and country-level policy scans to provide a fuller picture of women’s access in specific contexts. This phase is on-going, with final data expected in September.

Few examples exist of HIV treatment access analyses in which women with HIV are placed at the center of design and implementation.

Women living with HIV led the design and implementation of the review as they are best positioned to frame and prioritize the issues and areas that should be interrogated as part of an effort to fill these gaps. A Global Reference Group (GRG) of women living with HIV was constituted to guide the project throughout all phases. The 14 GRG members represent 11 countries and a range of diverse identities and experiences. The GRG was included in the development and revision of parameters for the extensive literature review, framing of priority topics and questions for a discussion guide used for FGDs and one-to-one interviews led by GRG members and other women living with HIV. Some GRG members are also involved in the final phase of the project, in-depth country case studies that probe issues and concerns raised in the previous phases.

This project is one of a limited set of investigations of women’s perspectives of why they choose to initiate and remain on or discontinue treatment. The project did not engage women who had never accessed ART, one of several areas for additional investigation.

“ I take nine pills, I have a sore throat, for 18 years I am taking tablets – I used to take up to 22 tablets – they are large tablets. ... That’s why sometimes I stopped taking them ... the routine of the drug already has me tired.”

INTERVIEW, BOLIVIA
Challenges

✱ Available data on rates of initiation and retention on ART are often not disaggregated by age and sex/gender and are not comprehensive for women who are not pregnant or breastfeeding.

✱ 73% of all pregnant women who have tested HIV-positive are on treatment, demonstrating that ART programmes are reaching women. However, for these women [and women in all their diversities for whom ART access data are missing] programmes do not serve their needs to facilitate remaining on ART over time, if they desire.

✱ Not addressing women’s treatment barriers can lead to lower levels of retention and adherence, diminishing the individual and public health benefits of treatment; including the uptake of early initiation and achievement of global epidemic control goals.

✱ An expanded definition of access that includes and addresses gender-related and structural barriers to starting and staying on treatment is needed.

✱ Additional, larger scale analysis of treatment access barriers with gender-related and structural barriers at the center, recognizing the intersectionality with other inequalities is needed.

✱ More research led by women living with HIV is needed. Recommendations will be put forward in the full report from the review due later in 2015.

Findings

Uneven progress in access and adherence

There have been improvements in access to ART and scale up of treatment programmes, but progress in addressing underlying factors that facilitate not only starting but remaining on treatment is uneven. Women face complex experiences accessing treatment; violence and discrimination from family, community members and healthcare professionals act as barriers or enablers to ART access.

Data gaps

✱ There are major gaps in the data collection. These include an absence of and/or gaps in data disaggregated by age and sex/gender at every stage of the treatment cascade (with the exception of women receiving ART as part of peri-natal services). There are also gaps in information on ART access for women in their full diversities [i.e. sex workers, transgender people, adolescent girls, young women and indeed women of any age who are not pregnant].

✱ Further gaps exist in relation to documentation of women’s experiences as patients, especially in relation to confidentiality, treatment literacy, disrespect and abuse.

✱ Based on available sex/gender-disaggregated data, women initiate ART more frequently than men, but many women do not remain on ART and may even have lower retention rates over the long-term than men.7 Option B+ rollout in several countries has been characterized by high levels of ‘loss to follow up’ and lower rates of adherence.8

Barriers

Micro-level (individual)

✱ Violence against women living with HIV: this, coupled with fear of violence, were the most commonly cited barriers for women.

✱ Fear and experiences of stigma and discrimination: this leads to non-disclosure of status, which is linked to lower adherence and higher rates of depression. This effect is amplified among women. Lack of privacy was also cited in relation to having no safe space at home or work to take medications.

✱ Side effects of HIV treatment: these were consistently cited as a barrier to treatment access in the form of long-term adherence for women, and some side effects – especially changes in body shape9 – had mental health or emotional repercussions, particularly around gender norms and expectations for women’s bodies and sexuality.


7. Women’s Working Group of APN+ [2009]. “A long walk – challenges to women’s access to HIV services in Asia: Participatory action research”.

I was really in favour of early treatment and to have this Option B+. But now my worry is: are we being given this as an option or is this being pushed on us with no option?” INTERVIEW, ZIMBABWE
Inability to meet basic needs: including livelihoods, food security, nutrition and housing, and each of these in turn served as a barrier to HIV treatment access and adherence. In the case of food security and nutrition, women reported prioritizing children over themselves making it difficult for women to access the healthy diets they need to take treatment effectively.

Meso-level (household, health service and community)

Gender roles and responsibilities: including women having to ask permission from husbands or other family members to seek services. This is a significant barrier to treatment access, as is the related lack of access to and control of resources that would allow women to move freely.

Violations of rights to privacy, confidentiality and bodily integrity in healthcare services: these were frequently cited as barriers to accessing treatment, particularly for women from key populations. Violations include: disclosure of HIV status in front of family members and other staff and clients; refusal of treatment and care for themselves and their children; human rights violations during and after labour, as well as forced and coerced sterilization.

Poor communication in healthcare: limited time with and effort by healthcare providers to address women’s concerns and deliver full information, including outlining the benefits and complications of treatment, what to take and when, and drug interactions that are frequently ignored or dismissed by healthcare staff. Women cited a lack of counselling, being unable to ask questions, side effects not being discussed, and being pressurized to make quick decisions without adequate information.

Mental health and self-stigma: women described experiencing internalized stigma resulting in depression, low self-esteem and self-worth, and other mental health problems. These can impact on their health-seeking behaviours, including treatment access and adherence.

Care-giving responsibilities: women’s expected role of caregiver was cited as a barrier to treatment. Women described taking children to the clinic due to unavailable or unaffordable childcare, and missing appointments due to family caregiving responsibilities.

Stigma and discrimination: women from marginalized groups [i.e. women engaged in sex work, transgender women, women who inject drugs] or partners of men who are at increased risk of HIV, face high levels of stigma and discrimination in healthcare settings and the community that impede their access to treatment.

Macro-level (national and policy)

Punitive laws, including criminalization: these exacerbate structural and community violence against women living with HIV and/or from key affected populations and impede access to treatment.

Facilitators

Women reported strong positive experiences with peer-led treatment literacy and support groups, with these experiences directly linked to accessing and remaining on ART over time.

Women cited building trusting relationships with healthcare providers as important to staying on treatment.

Many women reported finding strength, value and motivation from their roles within families as mothers, partners and caregivers, as well as leaders within their communities.

It motivates me when I look at my children and my other siblings, who are negative, and my father. I have to push on with life.”

INTERVIEW, UGANDA

The way forward

Antiretroviral therapy has never been more central to the global discourse on how to begin to end the HIV epidemic. Yet ART can only be effectively delivered in a rights-based context. Ambitious goals coupled with adequate, sustained resources and innovative rights-based programming will be what makes these goals achievable. However, there is no end to the epidemic without a specific agenda for addressing barriers to access that is implemented by and for women living with HIV in all their diversities.

An intentional, nationally-endorsed, community-led, demand-driven and sustainably funded service delivery model that addresses gender equality and women’s rights at household, family, community and national/institutional levels, will be essential to ensure that women who wish to initiate ART are supported to make an informed choice about whether and when to do so and, critically, to be able to remain on ART, if desired, over time.